1. Inicio
  2. Publicaciones
  3. [[Translated article]]Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP).

[[Translated article]]Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP).

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Couselo-Rodríguez C
  • Batalla A
  • Carrascosa JM
  • Chicharro P
  • González-Quesada A
  • de la Cueva P
  • Giménez-Arnau AM
  • Gilaberte Y
  • Montero-Vilchez T
  • Ruiz-Villaverde R
  • Elosua-González M
  • Silvestre-Salvador JF
  • Munera-Campos M
  • Sánchez-Pérez J
  • Carretero G
  • Mauleón-Fernández C
  • Curto-Barredo L
  • Ballano-Ruiz A
  • Arias-Santiago S
  • Navarro-Triviño FJ
  • Roustan-Gullón G
  • Betlloch I
  • Del Alcázar E
  • Abalde-Pintos MT
  • Suárez-Perez J
  • García-Doval I
  • Descalzo MÁ
  • Flórez Á

Grupos

Abstract

BACKGROUND: The past 5 years have seen a proliferation of new treatments for atopic dermatitis (AD). We analyzed recent drug survival data for cyclosporine in this setting. Because the Spanish National Healthcare system requires patients with AD to be treated with cyclosporine before they can be prescribed other systemic treatments, drug survival for cyclosporine may be shorter than in other diseases. MATERIAL AND METHODS: Multicenter, observational, prospective cohort study using data from the Spanish Atopic Dermatitis Registry (BIOBADATOP). Data from the Spanish Registry of Systemic Treatments in Psoriasis (BIOBADADERM) were used to create a comparison cohort. RESULTS: We analyzed data for 130 patients with AD treated with cyclosporine (median drug survival, 1 year). Median cyclosporine survival in the psoriasis comparison group (150 patients) was 0.37 years. Drug survival was significantly longer in AD than in psoriasis (P<.001). CONCLUSIONS: Drug survival of cyclosporine in the BIOBADATOP registry is similar to that described in other series of patients with AD and longer than that observed in the BIOBADADERM psoriasis registry.

Copyright © 2023 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
0001-7310, 1578-2190

Actas Dermo-Sifiliograficas  ELSEVIER ESPANA

Tipo:
Article
Páginas:
341-346
PubMed:
38325545
Factor de Impacto:
0,279 SCImago ℠
Cuartil:
Q3 SCImago ℠

Citas Recibidas en Web of Science: 2

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Atopic, Cyclosporine, Dermatitis, Survival analysis

Cita

Compartir